SITC Meeting | Conference

ICT01 With or Without Pembrolizumab Shows Early Safety, Activity in Advanced Solid Tumors

November 15th 2021

ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, has demonstrated early signs of biological activity when given as a single agent or in combination with pembrolizumab in patients with advanced solid tumors.

Eftilagimod Alpha/Paclitaxel Combo Shows Improved OS in Metastatic HR+ Breast Cancer Subsets

November 12th 2021

The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.

PD-L1/4-1BB–Directed Bispecific Antibody ATG-101 Shows Preclinical Efficacy Without Hepatotoxicity

November 12th 2021

ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys.

Innate Cell Engager Demonstrates Evidence of Improved EGFR Inhibition in Tumor Cell Lines

November 12th 2021

The innate cell engager AFM24 showed greater efficacy in eliciting antibody-dependent cellular phagocytosis of EGFR wild-type and KRAS-mutant tumor cells compared with cetuximab.

DuoBody®-CD3x5T4 Induces Efficient T-cell Activation, Tumor Cell Killing in HNSCC Cell Lines

November 12th 2021

The DuoBody®-CD3x5T4 was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and patient-derived head and neck squamous cell carcinoma cell lines.

Nivolumab/Ipilimumab Combo Is Effective, Safe in Advanced or Unresectable Angiosarcoma

November 13th 2020

November 13, 2020 - The combination of nivolumab and ipilimumab elicited an objective response rate of 25% and was found to be well tolerated in patients with advanced or unresectable angiosarcoma, according to cohort findings of the phase 2 DART trial.

STING Agonist Plus Atezolizumab Could Expand Immunotherapy Benefit to Nonresponsive Advanced Solid Tumors

November 13th 2020

November 13, 2020 - In an effort to expand the benefit of immunotherapy to nonresponders or those who have relapsed, the novel STING agonist SB 11285 is being evaluated as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors in a phase 1/1b dose-escalation trial.

Intratumoral Electroporation of pIL-12 Plus Pembrolizumab Elicits Durable Responses in PD-1–Refractory Advanced Melanoma

November 13th 2020

November 13, 2020 - The addition of plasmid IL-12 pembrolizumab resulted in durable responses, as well as several complete responses, in patients with advanced melanoma who were refractory to PD-1–directed therapy.

Dr. Campbell on the Expanding Role of Cabozantinib in RCC

November 12th 2020

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.

Dr. Hutson on Remaining Questions With the Durability of Immune Responses in RCC

November 12th 2020

Thomas Hutson, DO, PharmD, discusses remaining questions regarding the durability of responses to immunotherapy in patients with renal cell carcinoma.

Dr. Zhang on the Combination of LAG525 and Spartalizumab in Advanced Malignancies

November 12th 2020

Tian Zhang, MD, discusses the combination of ieramilimab and spartalizumab in advanced malignancies.

Pembrolizumab Shows Intriguing Benefit in Leptomeningeal Metastasis From Solid Tumors

November 12th 2020

November 12, 2020 — Pembrolizumab led to a 38% central nervous system response rate and was well tolerated in patients with leptomeningeal metastasis from solid tumors. However, the study was closed early due to poor accrual.

Cosibelimab Elicits Early Activity in NSCLC and Cutaneous Squamous Cell Carcinoma

November 12th 2020

November 12, 2020 - The investigational PD-L1 inhibitor cosibelimab demonstrated durable and robust responses in patients with non–small cell lung cancer and cutaneous squamous cell carcinoma.

CMP-001 Plus Pembrolizumab Elicits Deep Responses, Reverses PD-1 Resistance in Advanced Melanoma

November 12th 2020

November 12, 2020 - The combination of CMP-001 intratumoral injection and pembrolizumab was found to reverse PD-1 blockade resistance and elicit durable systemic responses in patients with advanced melanoma.

Cemiplimab Elicits Antitumor Activity in Metastatic Basal Cell Carcinoma

November 12th 2020

November 12, 2020 - Cemiplimab demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma after progression on or intolerance to hedgehog inhibitors

Dr. Hong Discusses IPI-549 in Advanced Solid Tumors

November 17th 2017

David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses IPI-549 during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Dr. Paulson Discusses Acquired Resistance to Immunotherapy

November 17th 2017

Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Novel Combination Shows Promising Responses in Pancreatic Cancer

November 12th 2017

The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.

Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma

November 12th 2017

Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.